ClinicalTrials.gg
RecruitingNCT07776054Updated Aug 20, 2026

Clinical Impact of SGLT2 Inhibitor After DC Cardioversion in Persistent AF With HFpEF

A Phase 4 interventional study of SGLT2 inhibitors (Dapagliflozin and Empagliflozin) in Atrial Fibrillation, SGLT2 Inhibitor and DC Cardioversion, sponsored by Samsung Medical Center. Recruiting at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-08-20.

Sponsored by Samsung Medical Center · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 2 years 6 months after the study started (first participant enrolled Feb 2024, registered Aug 2026).
  • Started Feb 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies testing SGLT2 inhibitors in Atrial Fibrillation — 9 open to participants now, 10 under way, 5 of them phase 3. A drug class: SGLT2 inhibitors · Atrial Fibrillation.

Planned enrollment
9th of 15
200 · median 280
Started
2024
with 3 others
Phase 4
5 of 15
3 open now
Registered
15th of 15
by date
Lead sponsor
1 of 15
Samsung Medical Center

Among the 15 studies testing SGLT2 inhibitors in Atrial Fibrillation, this one is the 9th largest by planned enrollment, is one of 4 that started in 2024, is one of 5 in phase 4, and was the 15th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

9 of the 15 studies testing SGLT2 inhibitors in Atrial Fibrillation are open now, in 7 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About SGLT2 inhibitors

A class of medicines: which ones, and the studies of each, are on its page →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing SGLT2 inhibitors in Atrial Fibrillation, or all of them as a file.
02

Study summary

SGLT2 inhibitors improve outcomes in heart failure across the ejection fraction spectrum, but their effect on maintenance of sinus rhythm after rhythm-control therapy is largely unknown. This prospective, single-center, open-label randomized controlled trial evaluates whether an SGLT2 inhibitor started after successful electrical cardioversion reduces recurrence of atrial tachyarrhythmia at 1 month in patients with persistent atrial fibrillation and heart failure with preserved ejection fraction. 200 patients will be randomized 1:1 to receive an SGLT2 inhibitor or no SGLT2 inhibitor.

Read the detailed description

Patients with persistent atrial fibrillation who meet HFpEF diagnostic criteria (H2FPEF ≥6 or HFA-PEFF ≥5) are screened. After at least 4 weeks of anticoagulation and exclusion of intracardiac thrombus by transesophageal echocardiography, electrical cardioversion is performed with a biphasic defibrillator. Patients who restore sinus rhythm and provide written informed consent are randomized 1:1, stratified by AF duration and left atrial size. All patients receive anticoagulation and antiarrhythmic drugs for 1 month per current guidelines, at the discretion of the treating physician. The primary endpoint is recurrence of atrial tachyarrhythmia at 1 month, assessed by 12-lead ECG or continuous monitoring (≥30 seconds). Analyses follow the intention-to-treat principle, with per-protocol analysis as a sensitivity analysis. The sample size of 200 provides approximately 90% power at a two-sided alpha of 0.05 to detect a difference in recurrence (24% vs 47%).

03

Conditions studied

  • Atrial Fibrillation
  • SGLT2 Inhibitor
  • DC Cardioversion

Browse trials for

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥19 years
  • Persistent atrial fibrillation
  • H2FPEF score ≥6 or HFA-PEFF score ≥5
  • Restoration of sinus rhythm after electrical cardioversion

Exclusion criteria

Exclusion Criteria:

  • Previous use of an SGLT2 inhibitor
  • Intracardiac thrombus on transesophageal echocardiography
  • Refusal to participate
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    SGLT2 inihibitor

    Patients receive an SGLT2 inhibitor (empagliflozin or dapagliflozin) after successful DC cardioversion, in addition to guideline-directed anticoagulation and antiarrhythmic drugs for 1 month.

    Drug: SGLT2 inhibitors (Dapagliflozin and Empagliflozin)

  • No intervention
    Control

    Patients receive guideline-directed anticoagulation and antiarrhythmic drugs after DC cardioversion, without an SGLT2 inhibitor.

Interventions

  • DrugSGLT2 inhibitors (Dapagliflozin and Empagliflozin)

    Drug page: SGLT2 inhibitorsStudies of SGLT2 inhibitorsSGLT2 inhibitors pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients receive an SGLT2 inhibitor (empagliflozin or dapagliflozin) after successful DC cardioversion, in addition to guideline-directed anticoagulation and antiarrhythmic drugs for 1 month.

06

What researchers measure

Primary outcomes

  1. Recurrence of atrial tachyarrhythmia

    Composite of atrial fibrillation, atrial flutter, and atrial tachycardia, documented on 12-lead ECG or as an episode lasting ≥30 seconds on continuous ECG monitoring.

    Time frame: 1 month after randomization (±1 week)

Secondary outcomes

  1. Recurrence of atrial fibrillation

    atrial fibrillation documented on 12-lead ECG or as an episode lasting ≥30 seconds on continuous ECG monitoring.

    Time frame: 1 month after randomization (±1 week)

  2. Recurrence of atrial flutter

    atrial flutter documented on 12-lead ECG or as an episode lasting ≥30 seconds on continuous ECG monitoring.

    Time frame: 1 month after randomization (±1 week)

  3. Recurrence of atrial tachycardia

    atrial tachycardia documented on 12-lead ECG or as an episode lasting ≥30 seconds on continuous ECG monitoring.

    Time frame: 1 month after randomization (±1 week)

  4. Stroke

    Time frame: 1 month after randomization (±1 week)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Aug 2027, 42 months after the start.

Of 130 non-industry phase 4 interventional studies under Atrial Fibrillation, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 81. This study's planned 42 months is below that.

Counting every sponsor, half of 142 studies reached it within 48 months; a quarter within 27 and three quarters within 81.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2026
First posted
Aug 20, 2026
StartActual
Feb 1, 2024
Primary completionEst.
Aug 1, 2027
CompletionEst.
Sep 1, 2027
Last update
Aug 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07776054
Responsible party
Juwon Kim (Assitant Professor, Samsung Medical Center) — Principal investigator
First posted
Aug 20, 2026
Start date
Feb 1, 2024
Primary completion
Aug 1, 2027 (estimated)
Completion
Sep 1, 2027 (estimated)
Last update
Aug 20, 2026

Study contacts

Juwon Kim
Contact
abcd186a@naver.com
+82-2-3410-2578

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SGLT2 inhibitors

Start the discussion